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Abstract
Myotonic dystrophy type I (DM1) is an autosomal dominant disease of which
clinical manifestations resemble premature aging. We evaluated the contribu-
tion of telomere length in pathogenesis in 361 DM1 patients (12 with serial
measurements) and 223 unaffected relative controls using qPCR assay. While
no differences in baseline leukocyte relative telomere length (RTL) was noted,
the data suggested an accelerated RTL attrition in DM1 (discovery cohort: T/S
change/year = 0.013 in DM1 vs. 0.005 in controls, P = 0.04); similar trend
was noted in validation cohort. Further investigations are needed to examine
the role of TL in the pathophysiology of DM1.
Introduction
Myotonic dystrophy type 1 (DM1) is an autosomal
dominant multisystem disorder resulting from an unsta-
ble trinucleotide (CTG)n repeat expansion in the 3’
untranslated region of the dystrophia myotonica-protein
kinase (DMPK) gene.1 Clinical manifestations of DM1
include progressive muscle weakness and wasting, myoto-
nia, premature cataracts, cardiac conduction defects, gas-
trointestinal/endocrine abnormalities, and increased risk
of certain cancers.2,3 It has been suggested that the DM1
phenotypes may resemble a premature aging syndrome.4
Telomeres are tandem hexanucleotide (TTAGGG)n
repeats and protein complexes at the end of chromo-
somes, maintaining genomic stability.5 They shorten with
each cell division6 and are marker of cellular aging. Few
studies suggested a link for telomere length in the patho-
genesis of Duchenne (DMD) or limb girdle muscular dys-
trophies.7,8 Telomere length studies in DM1 were limited;
an in vitro investigation using DM1 muscle precursor cells
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from three fetuses with congenital DM1 showed abnormal
accumulation of P16 and higher telomere attrition per
cell division compared with controls.9
Here we compared leukocyte relative telomere length
(RTL) in a large cohort of genetically- confirmed DM1
patients and DM1 mutation-free clinically healthy relative
controls and evaluated telomere length attrition overtime
in a subset of patients with serial blood samples.
Materials and Methods
Study participants
We used data and samples from 379 DM1 patients and
235 DM1-free relative controls from the Spanish Guipuz-
coa historical myotonic dystrophy cohort.10 Participants’
demographics and clinical information were obtained
through medical records review. We excluded 30 individ-
uals (28 missing age, one twin, and one with failed qual-
ity control metrics for RTL assay). The final analysis
included 361 DM1 patients and 223 controls. Twelve par-
ticipants provided a second sample for RTL measurement,
as convenience permitted.
The study was approved by the Donostia University
Hospital Ethical Board and by the Office of Human Subjects
Research Protections at the National Institutes of Health.
DNA extraction and telomere length
measurement
Blood DNA was extracted using the salting out procedure or
Qiagen Flexigen DNA kit (QIAGEN, Germantown, MD).
We measured RTL after adapting the originally published
quantitative polymerase chain reaction (qPCR) method.11
Method details are available elsewhere.12 Briefly, qPCR assay
measures a ratio between telomere repeats amplification (T)
to that of an autosomal single-copy gene (S; 36B4). The T/S
ratio then get normalized using internal QC calibrator sam-
ples to yield a standardized T/S ratio. All samples were
assayed in triplicate. The coefficient of variation for internal
control samples was 4.5%.
Statistical analysis
All analyses were stratified by DNA extraction method to
account for known variable qPCR sensitivity to extraction
method.13 Samples extracted by salting out (N = 223
patients and 162 controls) served as a discovery cohort,
and those extracted by Qiagen Flexigen DNA kit
(N = 138 patients and 61 controls) served as a validation
cohort. RTL data from serial samples extracted by the
same method were available for 12 DM patients (N = 7
for discovery, N = 5 for validation cohort).
We used generalized linear models to compare the
mean RTL between DM1 and controls, and in DM1
patients by CTG repeat size categories (40–50, 51–249,
250–499, ≥500). A random intercept linear mixed model
was used for repeated measurement analysis; RTL annual
attrition rate in DM1 patients with repeated samples
(median time between samples = 9 years, range = 4-
17 years in the discovery, and median time = 3 years,
range = 2–3 years in the validation) was compared with
that expected from regression models of RTL and age
using control cross-sectional data using R package
‘lme4’. Differences in RTL attrition rates between DM1
patients and controls was assessed by an interaction term
between DM1-control status and age. Statistical analyses
were conducted using SAS version 9.4 and R version
3.4.4.
Results
Characteristics of study participants
DM1 patients and controls showed similar ages (median
age = 42.0 and 43.0 years in DM1 vs. controls, respec-
tively) and sex distributions (proportion of
males = 45.7% and 43.9% in DM1 vs. controls, respec-
tively). No age or sex differences were noted between
DM1 patients in the two study subsets, or between
patients and relatives in each set (P > 0.05). Patients with
DM1 in the discovery and validation cohorts also had
similar CTG repeat size (median repeat size = 433 and
500 for discovery vs. validation cohorts, respectively,
P = 0.37) (Table S1).
In DM1 patients, the size of CTG repeat was inversely
correlated with age at genetic testing in both discovery
(r = 0.26, P = 0.0003) and validation cohorts
(r = 0.21, P = 0.02) (Fig. S1A-B).
The patients with a second blood sample showed simi-
lar age, and sex distribution. However, despite of lack of
statistical significance, the data suggested that patients
with subsequent sample may have a less severe disease as
evident by shorter CTG repeat sizes (median = 167 vs.
500, in those with and without subsequent sample, respec-
tively) and less Muscular Impairment Rating Scale (MIRS)
(0% vs. 24% with MRIS > 3, respectively) (Table S2).
Telomere length in DM1 patients and
controls
RTL was inversely correlated with age among both DM1
patients and controls (discovery cohort: r = 0.39,
P < 0.0001 for DM1 and r = 0.51, P < 0.0001 for con-
trols; validation cohort: r = 0.27, P = 0.002 for DM1
and r = 0.23, P = 0.07 for controls; Fig. S2A-B).
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No differences were observed in RTL between DM1
patients and controls at baseline: discovery cohort: (mean T/
S  SD) = 0.62  0.20 and 0.60  0.16 for DM1 and con-
trols, respectively, P = 0.13; or in the validation cohort:
(mean T/S  SD)=0.42  0.12 and 0.43  0.12, respec-
tively, P = 0.78, Fig. 1A and B). Age- and sex-adjustment
did not alter the results. In DM1 patients, RTL was not asso-
ciated with CTG repeat expansion size, nor with MIRS in
models adjusted for age and sex (Fig. 2A and B).
Telomere length attrition overtime in
patients with DM1
Baseline RTL was similar in patients with and without
repeated RTL measurements (median T/S = 0.58 vs. 0.52,
P = 0.27).
In the repeated RTL measurement analyses, and when
compared with expected based on RTL attrition from rela-
tives’ cross-sectional data, a more rapid RTL decline was
noted in DM1 in the discovery cohort (T/S decline/
year = 0.013 vs. 0.005 for DM1 and controls, respec-
tively, P = 0.04). A similar (non-significant) trend was
noted in the validation cohort (T/S decline/year = 0.005
vs. 0.002, P = 0.33) (Fig. 3A and B, Table S3).
Discussion
In this analysis of a large cohort of patients with geneti-
cally confirmed DM1 and clinically healthy relative con-
trols, we observed no difference in leukocyte RTL
measured at genetic testing between patients and controls,
yet, a higher rate of annual telomere length attrition was
noted in DM1 patients.
Prior DM1 telomere length studies have been limited
to few small in-vitro investigations focusing on its possi-
ble role in muscle precursor cell dysfunction. In agree-
ment with our results of similar leukocyte RTL in DM1
and controls, a study comparing telomere length in distal
(with clinical and pathological alterations) and proximal
muscles (relatively spared) from four DM1 patients
showed no telomere length difference.14 Yet, we showed
a higher rate of RTL attrition overtime in DM1 patients
than expected based on RTL attrition rate from controls.
Our findings were also consistent with a study of muscle
satellite cells in fetuses/infants with congenital DM1
which showed a faster telomeric DNA loss per cell divi-
sion (171.9  17 base pairs) when compared with con-
trol cells (108.1  10 base pairs); the authors concluded
that large CTG expansion repeats may interfere with
telomere homeostasis in those patients.9 Of note, we
found no association between patients’ leukocyte RTL
and CTG repeat size; suggesting no direct role for repeat
expansion size in the observed telomeric attrition. How-
ever, our data were limited by the unavailability of pro-
genitor repeat size. Also, testing this hypothesis in blood
cell (not known to be affected in DM1), may not be
directly applicable to somatic changes in affected organs
such as the muscles. Somatic mosaicism and instability
in repeat expansion size are well-described in DM1.15 It
is possible that the accelerated telomere attrition
observed in our DM1 patients is a consequence of the
cellular exposure to oxidative stress. The triple-guanine
sequence in telomeric DNA (TTAGGG)n is very sensitive
to oxidative damage,16 resulting in accelerated telomere
shortening.17 Previous studies have shown a significant
increase in blood level of free radicals and oxidative
Figure 1. Comparison of relative telomere length between DM1 patients and their healthy relative controls. (A) Discovery cohort, (B) Validation
cohort.
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stress biomarkers in DM1 patients,18,19 suggesting a role
for oxidative stress in disease progression.
The observed differences in the rate of TL attrition
between the discovery and validation cohort could be
affected by the difference in the time interval between
samples (median interval = 9 years in the discovery, and
3 years in the validation). It has been shown that TL
elongation in longitudinal studies is mostly artifact related
to measurement errors in studies with short follow-up
(≤5 years) where TL changes are usually small and hard
to capture.20
Our study strengths include a relatively large sample
size, the genetic diagnosis confirmation, the objectively
healthy status of controls, and the availability of repeat
expansion size. Limitations include the small sample size
of patients with serial samples, who were not systemati-
cally sampled. Due to short time period between blood
sampling, observed TL elongation in some patients could
be artifactual.20 Our control data were based on baseline
measurement of RTL in relatives because of the unavail-
ability of serial samples; a prior study has shown small
differences in TL attrition rate calculated from cross-
Figure 2. Relative telomere length in DM1 patients by CTG repeat size and by Muscular Impairment Rating Scale (MIRS) in age- and sex-adjusted
models. (A) CTG repeat size, (B) Muscular Impairment Rating Scale.
Figure 3. Comparison of annual relative telomere length attrition between DM1 patients and their healthy relative controls. (A) Discovery cohort,
(B) Validation cohort.
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sectional or longitudinal data in the general population
(24.6 vs. 31 bp per year).20 The qPCR assay is sensitive
to pre-analytic processing, notably DNA extraction
method. Consequently, we presented our results stratified
by DNA extraction method. Although similar trends
were observed in the two datasets, we cannot rule out
the possibility that the difference in DNA extraction
methods and/or time between serial samples contributed
to the observed difference in the rate of TL attrition
between the two sets.
In conclusion, our results suggest that telomere short-
ening does not play a direct role in DM1 etiology but
may be a consequence of molecular alterations over time,
possibly secondary to oxidative stress. It is possible that
accelerated telomere shortening may mediate the age-re-
lated phenotypic presentation of DM1.
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Figure S1. Correlation between CTG repeat size and age
in DM1 patients. A. Discovery cohort, B. Validation
cohort
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Figure S2. Correlation between relative telomere length
and age. A. Discovery cohort, B. Validation cohort
Table S1. Baseline characteristics of DM1 patients and
their unaffected relative controls, stratified by DNA
extraction method
Table S2. Comparison of baseline characteristics of DM1
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